Search the Newsreel

Wave Life Sciences Ltd earnings missed by $0.04, revenue fell short of estimates

Wave Life Sciences Ltd (NASDAQ: WVE) reported a second-quarter EPS of $-0.340, missing analyst estimates by $0.04, and revenue of $2.3M, which fell short of the $7.65M consensus. The company's stock has seen a significant decline over the past 3 and 12 months, with …

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences (Nasdaq: WVE) announced its second quarter 2026 financial results, highlighting significant progress in its clinical pipeline. Key updates include ongoing dosing in a Phase 2a trial for WVE-007 for obesity, with plans to initiate Phase 2 combination trials later in 2026. …

Wave Life Sciences Ltd. Q2 2026: Revenue $2.3M, EPS $(0.34) — 10-Q Summary

Wave Life Sciences Ltd. reported Q2 2026 results with $2.3 million in revenue and a diluted loss per share of $0.34. This reflects a decrease in collaboration revenue and continued investment in research and development. Despite the quarterly decline, six-month revenue increased significantly due …

Wave Life Sciences Shares Fall After Wider Q2 Net Loss, Lower Revenue

Wave Life Sciences Ltd. Q2 2026 Earnings Call Summary

Wave Life Sciences: Q2 Earnings Snapshot

Wave Life Sciences Pte. Ltd. (WVE) reported a Q2 loss of $69.4 million, or 34 cents per share, which was worse than Wall Street's expectation of a 31-cent loss per share. The biopharmaceutical company also posted revenue of $2.3 million, falling short of the …

Wave Life Sciences earnings loom: investors brace for revenue drop By Investing.com

Wave Life Sciences Ltd. is set to announce its second-quarter earnings, with analysts projecting a significant sequential revenue decrease to $7.45 million, contrasting sharply with the previous quarter's $38.25 million. This expected drop highlights the episodic nature of collaboration payments typical for pre-commercial biotech …

WAVE Life Sciences Ltd Today's Market Trends | WVE Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

WAVE Life Sciences Ltd (WVE) is a biotechnology company focused on RNA medicines. The article provides real-time quotes, market trends, financial indicators, and analyst ratings, showing a "Buy" consensus with a target price of $23.00. Despite a recent market decline, the company exhibits strong …

WAVE Life Sciences Ltd (WVE) Financial Health: Profitability & Balance Sheet Analysis

WAVE Life Sciences Ltd (WVE) has a robust financial health score of 9.50, ranking 3rd in its industry. The company reported significant financial growth with a 316.85% year-over-year increase in quarterly revenue and a 44.35% increase in net profit. Key financial indicators like quality …

Wave Life Sciences Ltd. Revenue Breakdown – NASDAQ:WVE

Wave Life Sciences Ltd. (NASDAQ: WVE) generated $42.73 million USD in revenue last year, primarily from its Stereopure Oligonucleotides segment. This marks a decrease from the previous year's revenue of $108.30 million USD. The main revenue contributions came from Singapore, the United States, Japan, …

Wave Life Sciences Ltd (WVE) News, Articles, Events & Latest Updates

This page provides recent news and updates for Wave Life Sciences Ltd (WVE), including several articles from Zacks Investment Research. Key updates indicate that WVE has been upgraded to a Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) due to growing optimism …

Wave Life Sciences to report Q2 2026 financial results on July 30

Wave Life Sciences Ltd. (NASDAQ: WVE) is scheduled to release its second quarter 2026 financial results on July 30, 2026. The company will host a live webcast and conference call at 8:30 a.m. ET to discuss the financial performance and provide business updates, including …

Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales

Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?

Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating a positive shift in its earnings outlook. This upgrade is based on upward revisions in earnings estimates, which Zacks analysis suggests is a powerful predictor of near-term stock price …

Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In?

Wave Life Sciences (WVE) has seen recent share price fluctuations, with a weak short-term trend but strong long-term returns. Investors are divided, with one narrative suggesting the stock is undervalued at $22.19 based on its RNA pipeline and upcoming clinical data, while another view …

Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings Report - Results, Call & Slides

Wave Life Sciences (WVE) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.29 against a consensus of -$0.26 and actual revenue of $9.18 million compared to an expected $11.92 million. The revenue marked …